Immunic (IMUX) Equity Ratio (2013 - 2026)

Immunic has disclosed Equity Ratio across 14 years of filings, most recently posting 0.8 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.8, up 409.28% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.8 (up 409.28% YoY), and the FY2025 annual result was 0.28, down 161.52% from the prior year.
• Equity Ratio came in at 0.8 for Q1 2026 at Immunic, up from 0.28 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.92 in Q2 2022 to a low of 0.28 in Q4 2025.
• The 5-year median for Equity Ratio is 0.74 (2024), against an average of 0.6.
• Across the five-year window, Equity Ratio tumbled 161.52% in 2025 and soared 409.28% in 2026, its largest moves.
• Immunic's Equity Ratio stood at 0.89 in 2022, then plunged by 40.13% to 0.53 in 2023, then retreated by 15.37% to 0.45 in 2024, then sank by 161.52% to 0.28 in 2025, then surged by 387.29% to 0.8 in 2026.
• The last three Equity Ratio figures came in at 0.8 (Q1 2026), 0.28 (Q4 2025), and 0.26 (Q3 2025), per Business Quant data.